Targeting the delivery of dietary plant bioactives to those who would benefit most: from science to practical applications

Baukje de Roos1 · Anna-Marja Aura2 · Maria Bronze3 · Aedin Cassidy4 · Maria-Teresa Garcia Conesa5 · Eileen R. Gibney6 · Arno Greyling7 · Jim Kaput8 · Zohar Kerem9 · Nada Knežević10 · Paul Kroon11 · Rikard Landberg12 · Claudine Manach13 · Dragan Milenkovic13 · Ana Rodriguez-Mateos14 · Francisco A. Tomás-Barberán5 · Tom van de Wiele15 · Christine Morand13

Received: 11 April 2019 / Accepted: 2 August 2019 / Published online: 22 October 2019 © The Author(s) 2019

Abstract

Background. A healthy diet and optimal lifestyle choices are amongst the most important actions for the prevention of cardiometabolic diseases. Despite this, it appears difficult to convince consumers to select more nutritious foods. Furthermore, the development and production of healthier foods do not always lead to economic profits for the agro-food sector. Most dietary recommendations for the general population represent a “one-size-fits-all approach” which does not necessarily ensure that everyone has adequate exposure to health-promoting constituents of foods. Indeed, we now know that individuals show a high variability in responses when exposed to specific nutrients, foods, or diets.

Purpose. This review aims to highlight our current understanding of inter-individual variability in response to dietary bioactives, based on the integration of findings of the COST Action POSITIvE. We also evaluate opportunities for translation of scientific knowledge on inter-individual variability in response to dietary bioactives, once it becomes available, into practical applications for stakeholders, such as the agro-food industry. The potential impact from such applications will form an important impetus for the food industry to develop and market new high quality and healthy foods for specific groups of consumers in the future. This may contribute to a decrease in the burden of diet-related chronic diseases.

Key messages

• Individual differences in ADME (Absorption, Digestion, Metabolism and Excretion) is believed to underpin much of the inter-individual variation in responses.
• Recent developments in the area of food metabolome databases and fast improvements in innovative metabotyping technologies hold great promise for improved profiling of dietary intake, exposure to individual ingredients, foods and dietary patterns, as well as our ability to identify individual responsiveness.
• The food industry needs well-defined population clusters or targets in order to be able to design “personalized products”.
• There are indeed excellent industrial opportunities for foods that modulate gut microbiota, and thereby enable the delivery of food bioactive metabolites.
• It is currently not clear whether knowledge on individual nutrient needs, based on genetic or metagenomic data, would affect long-term dietary and health behaviours.

This article is based upon work from COST Action FA1403 POSITIvE (Interindividual variation in response to consumption of plant food bioactives and determinants involved) supported by COST (European Cooperation in Science and Technology; www.cost.eu).

Baukje de Roos
b.deroos@abdn.ac.uk

Extended author information available on the last page of the article
• Data to support the development of dietary recommendations may need to be generated by new n-of-1-based study designs in the future.

Keywords Healthy diet · Cardiometabolic diseases · Inter-individual variability in responses · Stakeholders · Food industry

Abbreviations

ADME Absorption, digestion, metabolism and excretion
BMI Body mass index
COST European cooperation in science and technology
CVD Cardiovascular disease
JPI Joint-programming initiative
LDL Low-density lipoprotein
POSITIVe Inter-individual variability in cardiometabolic response to consumption of plant bioactives
RCT Randomised clinical trials
SNP Single-nucleotide polymorphism

Inter-individual variability in cardiometabolic response to consumption of plant bioactives

The COST Action POSITIVe, a multidisciplinary and cross-sectorial European network of top-level scientists from more than 70 research institutions in 32 countries, members of regulatory authorities, and representatives of the food industry, has been instrumental in highlighting the large magnitude of individual variation in responses of health biomarkers to interventions with plant bioactives [1]. Variability in response to intervention is often not accounted for in studies, is considered an inconvenient impediment for establishing the efficacy of these plant bioactives in population-based studies, and is masked by common statistical methods that generate an average for the population rather than the individual results. Rarely are results reported for all individuals in a study to fully describe the extent of variation, but when they are, the extent of the variation can be seen to be dramatic. For example, total urinary excretion of naringenin phase-2 conjugates from a fixed dose of orange juice ranged from 1.6 to 59% (37-fold difference) in a study of 129 participants [2]. Individual differences in ADME (Absorption, Digestion, Metabolism, and Excretion), which includes the role of gut microbiota in the metabolism of plant polyphenols and other bioactives, is believed to underpin much of the inter-individual variation in responses.

For example, the clustering of urolithin metabolotypes has helped to understand how inter-individual differences in the metabolism of pomegranate ellagitannins can be linked to individual differences in responsiveness in cardiovascular risk biomarkers [3]. In addition, a recent review that was executed as part of the COST Action POSITIVe highlighted the large range of factors, including age, BMI, sex, Helicobacter pylori infection, blood lipids, drug intake, microbiota as well as genetic polymorphisms (e.g., SNPs or single-nucleotide polymorphisms) that are known (and speculated) to influence carotenoid metabolism and exposure [4]. A different example shows that variability in the activity of polymorphic carriers and post-absorptive phase I and II metabolizing enzymes that depend on age, sex, or genotype are believed to contribute to the heterogeneity in flavonoid ADME. A significant part of the inter-individual variability in flavonoid ADME may be attributed to genetic variability and the gene–environment interactions, although it is currently unclear which gene variants and environmental factors contribute to responses [5]. Flavonoid ADME are also highly dependant on gut microbiial metabolism—indeed, some of the microbiome-mediated bioconversions result in the production of metabolites with enhanced biological activity, with one of the best known examples being the conversion of soy isoflavones into equol [6]. Lignans constitute a similar example, where plant lignans are converted into mammalian lignans, enterdiol, and enterolactone by the gut microbiota. Main determinants of circulating enterolignans are plant lignan intake, composition, and activity of intestinal microflora, antimicrobial use, nutrient intake, BMI, smoking, sex, and age [7]. Polyphenols exemplify the complexity of metabolism of dietary secondary metabolites: computational analysis found that the most characterized 389 polyphenols interacted with 5699 unique proteins in an interactome of almost 12,000 interactions. These interactions mapped to a large number of diverse intermediary and regulatory pathways [8].

Inter-individual variation in response to food intake is a very recent development in nutrition and health. Knowledge of differences in metabolism of most plant food bioactives are currently limited to the inter-individual variances in plasma or urine concentrations of selected metabolites in controlled intervention studies. We only have scattered information on how the food matrix may affect the metabolism of plant food bioactives. In addition, molecular markers and genes of importance in ADME are typically unknown for individual compound groups. Extensive literature research completed as part of COST Action POSITIVe revealed a significant deficit in knowledge about the carriers, enzymes/isofoms, and gut bacteria involved in absorption and metabolic pathways, making it difficult to identify key molecular determinants of ADME variability. Furthermore, a limited number of clinical trials have suggested that metabolic or
related disease traits of individuals can also influence the responsiveness to the consumption of plant sterols and some polyphenols [9].

The COST Action POSITIVe group identified a number of common factors from published human studies that appear to affect responsiveness to plant food bioactives. Several meta-analyses suggested that the magnitude of the responses was generally larger in those who were overweight and in subjects at risk of, or currently diagnosed with cardiovascular disease (CVD). For example, the consumption of foods and/or derived products containing flavanols has been associated with a significant decrease in body mass index (BMI), waist circumference, and total and low-density lipoprotein (LDL) cholesterol in individuals with a BMI ≥ 25.0 kg/m² [10]. Similarly, in overweight and obese populations, the intake of food products containing ellagitannins was associated with a reduction in waist circumference, total and LDL cholesterol, triglycerides, glucose, and systolic blood pressure (SBP). Similarly, the intake of anthocyanin-containing products was associated with a significant reduction in both systolic (SBP) and diastolic blood pressure (DBP) [11]. These types of results indicate that overweight subjects may constitute a target group who would benefit most from the intake of these bioactive compounds.

Although numerous systematic reviews and meta-analysis have revealed that inter-individual variation in response to plant polyphenols is a real issue that warrants further investigation, the underlying concepts and methods of meta-analyses yield limited insights into determinants that drive responsiveness to dietary intervention in individuals. Indeed, many of the large randomised controlled trials (RTCs) have demonstrated that only ~40% of the trial participants respond to dietary interventions [12]. Currently, the nutrition and food research communities have not conducted the appropriately designed interventions, nor do they have the databases that would allow data fusion between studies or the grouping of individual data. Translating population attributable risks to individual risks or benefits has not been accomplished except for a few examples [13]. Despite this, a wide range of newly launched apps and tools create the impression that effective personalised diets can be recommended based on limited genetic and phenotypic profiles. These efforts are likely premature [14, 15] and could potentially damage the scientific reputation of the field and the ability for investments in the field of personalised and precision nutrition.

What is needed to deliver future impact for stakeholders?

To identify the current opportunities and future needs for translation of scientific knowledge on inter-individual variability in response to dietary bioactives into practical applications for stakeholders, we established the main stakeholders of the research field of inter-individual variability in response to diet (Fig. 1). The attendees consisted of a multidisciplinary and cross-sectorial European network of top-level scientists (nutritionists, clinicians, geneticists, epidemiologists, microbiologists, experts in gut micro biome and nutrigenomics, bioinformaticians, molecular biologists, and food scientists) from more than 70 research institutions in 32 European countries, members from regulatory agencies and representatives of the food industry. The results revealed that the food industry was perceived to be one of the most important stakeholders in this field, closely followed by academia, the nutraceutical industry, consumers, and to a lesser extend policy makers and regulatory agencies.

Here, we will discuss available tools, perceived limitations and requirements for each of these stakeholders groups to create collective impact on individual and public health outcomes in the future (Fig. 2).

Food and nutraceutical industry

The challenge for the food industry is to develop processed food products that are shelf-stable, inexpensive, attractive for consumers, and that contribute to healthier diets. Ideally, foods would be both desirable and healthy. However, consumers often select products that are not based on their needs to maintain or improve health. As such, it is important for the food industry to better understand consumer preferences, but also how these can be linked to scientifically proven health benefits. Developing, marketing, and selling these products would have the highest impact on individual and public health. However, regulations governing nutrition and health claims are mostly focused on health effects of individual nutrients in well-defined target groups. The result has been an overemphasis on single-functional ingredients as the basis for petitioning for health claims. Applications...
to regulatory agencies for health claims on foods and drinks throughout the European Union (Regulation 1924/2006 [16]) are expensive and time consuming, and require multiple rigorous scientific studies to substantiate a single claim. This is a disadvantage in a competitive market and, therefore, may discourage companies from making such investments. Nevertheless, the development of evidence-based marketing messages conveying positive health messages, advocating balanced intakes of manufactured and fresh foods that also account for nutrient security and sustainability, would contribute to short- and long-term needs of industry marketing strategies. Indeed, it is vitally important for a food industry that information from health claims can actually affect consumer understanding, purchase, and consumption [17]. The requirements for generating evidence for healthier foods limit research to larger companies that have sufficient revenue for long-term investment in research programmes. These often attempt to understand the entire chain from molecular mechanisms to evidence from human intervention studies. The timeline for such research intensive programmes is often too long to account for the rapidly changing consumer “preferences”. Examples are products that are gluten-free, organic, alternative protein or packaged in sustainable containers.

The challenges involved in the development of healthy foods, health claims, and marketing messages become even more complicated when considering a market, where the demand for personalised products has increased in recent years. In order for this new trend to prosper while supporting public health, the food industry needs to have well-defined population clusters or targets. These targets should extend beyond those defined by sex or age, and lead the design of “personalised products”. A survey across 84 stakeholders from large food companies (40%), the European food and drink sector (36%), SMEs (13%), dissemination organisations (6%), public health bodies (4%), and other stakeholders (food distributors, raw material suppliers, trade associations, pharmaceutical companies; 15%) highlighted that the majority of stakeholders and end-users believe that improved knowledge on the efficacy of plant bioactives can help to optimise product development. It is also shared by many that improving traditional foods—for example, by improving processing methods to increase bioavailability of health-promoting compounds from plants—will prove successful. The POSITIVE group also concludes that improved knowledge on the efficacy of plant bioactives can help to optimise product development, especially for specific age groups and lifestyle groups. This knowledge should support the extension of the range of popular products to provide personalised benefits to the targeted populations. One of the largest knowledge gaps in the research field is perceived to be knowledge of metabolism of plant bioactives in the human body, presented in databases (Fig. 3). There are indeed excellent industrial opportunities for foods that modulate gut microbiota, and thereby enable the delivery of food bioactive metabolites [18]. Moreover, the microbiota of the host appears to be an important determinant of the health effects of specific foods, and thus, assessment of subjects’ habitual microbiota or biomarkers thereof may be one strategy for tailoring foods for optimal effects across groups of individuals [19, 20].

**Academia**

In general, we lack studies that provide data on both the bioavailability of, and biological responsiveness to, plant
**Fig. 3** Survey outcomes highlighting key opportunities and requirements for the field of dietary plant bioactives amongst 84 key stakeholders from the food and drink sector, SMEs, dissemination organisations, public health bodies, food distributors, raw material suppliers, trade associations, and pharmaceutical companies.
bioactives, especially after standardized intake of plant bio-
actives [21, 22]. Studies are usually too small to allow the
identification of common factors influencing ADME, or to
stratify subjects based on responsiveness to identify effects
and mechanisms in more homogenous groups. Furthermore,
many studies rely on food intake data which does not neces-
sarily relate to individual exposure to, and bioavailability of,
plant bioactives. Last but not least, we lack robust and
database-driven opportunities for data fusion across RCTs
that allow aggregation of individual data to identify factors
that explain inter-individual variation in cardiometabolic
responses to plant bioactives.

The field would benefit from opportunities, where inter-
individual variability can be investigated in cohort studies
that facilitate multiple longitudinal samplings and metabolic
profiling of blood, urine, and the gut microbiome to ascer-
tain cardiometabolic responsiveness. In addition, the field
would benefit from large RCTs that collect information on
individual responsiveness to build the robust evidence-base
to mechanistically understand health benefits and establish
a cause and effect relationship. Study designs of such RCTs
should allow for comprehensive baseline profiling and mea-
sure genetic variation, gut microbiota composition, lifestyle,
and environment [23]. Recent developments in the area of
metabolomics as well as food metabolome databases, and
fast improvements in innovative metabotyping technolo-
gies [24–26] hold great promise for our ability to profile
dietary intake and exposure to individual ingredients, foods
and dietary patterns, as well as our ability to identify indi-
vidual responsiveness [27]. Combining these data sets would
improve the ability to establish high probability associations.
Indeed, metabotyping has been proposed as a stratification
tool based on ADME capacity, as has been done for equol
and non-equol producers after intake of soy isoflavones, uro-
lithin metabolotypes after the intake of pomegranate ellagitan-
inns [21], or for the urinary excretion of prenyl naringenin
after hops flavanone intake [28].

Data fusion approaches exploiting studies that have been
published, or are underway, may allow for the creation of
larger data sets that would have sufficient statistical power
to reveal relationships between endogenous factors and car-
diomtabolic health outcomes on the individual level. Such
approaches would also allow the implementation of novel
computational methods to extend additive genetic risk scores
to include nonlinear gene–gene, gene–environment, and epi-
getic interactions that influence responses to plant bioa-
tives and other nutritional variables [29]. However, we found
that data fusion approaches were inherently difficult because
of ethical and logistical factors that limit access to data
and that differences in study designs and outcomes make
it almost impossible to merge data. Notwithstanding, such
an approach is of great and common interest to researchers
working in this area, since it facilitates subgroup analyses
and gathers evidence for factors driving responsiveness in
individuals or groups of subjects that share similar character-
istics. Indeed, initiatives such as the European Joint Pro-
gramming Initiative (JPI; https://ec.europa.eu/programmes/
horizon2020/en/h2020-section/joint-programming-initi-
aves) a Healthy Diet for a Healthy Life require that data
collected by funded consortia are made publicly available.
Similarly, the medical research area has been working on
the establishment of specific requirements for third-party
access to anonymized individual data from clinical trial par-
ticipants [30]. This is not a trivial issue, but similar mecha-
nisms to achieve data integration in nutrition research should
be pursued by the combined efforts of researchers, clinical
trial units, nutritional journals, and international platforms.
The sum of these considerations leads to a requirement for
additional and extensive funding to perform new human
studies which include the conceptual and methodological
approaches to analyse variability in response.

Consumers

Recent evidence suggests that a personalised approach
based on an individual’s diet, phenotype, and environment
improves healthy eating patterns and choices, at least in the
short-term and in a research setting [31]. Such personalised
advice may coincide with an individual’s specific needs and
habits increasing the feeling of involvement and creating
a higher awareness. The public appears to be interested in
the adoption of personalised nutrition services, including
affordable, simple, and reliable gadgets for self-classification
and self-monitoring. Direct-to-consumer DNA testing for
personalised diets has spurred extensive scientific and ethi-
cal debates in the literature about the underlying knowledge
base for interpreting the results. In addition, consumers
may have reservations about a service providers’ ability to
ensure the secure handling of their personal health data [32].
A recent study revealed that health apps pose significant
privacy risks—sharing of private medical user data is rou-
tine, yet far from transparent for users and clinicians [33].
A Europe-wide study showed that consumers’ intention to
adopt personalised nutrition services depends more on per-
ceived benefit and effectiveness than on perceived privacy
risk. However, services requiring information of an individ-
ual’s DNA-raised consumers’ perceived privacy risk without
increasing perceived benefit [34]. Whether knowledge of an
individual’s nutrient needs based on genetic or metagenomic
data would affect long-term dietary and health behaviours is
still unknown. The recent Food4Me study showed that the
MTHFR genotype did not significantly improve intakes of
dietary folate [35], and a meta-analysis revealed no signifi-
cant effects of communicating DNA-based risk estimates on
health behaviours such as smoking, diet, physical activity,
alcohol and medication use, or indeed on motivation to change behaviour [36].

Most current personalised nutrition approaches provide dietary advice based on existing food products. Targeting new personalised foods to individuals or groups of individuals would have to be produced, marketed, and distributed to increasingly small consumer segments. The financial viability of products targeted at the group level is uncertain [37]. Indeed, personalised foods with controlled ingredient formulation will be more challenging to produce using existing manufacturing processes. Recent developments in emerging technologies (such as 3D printing) may provide new opportunities for the production of personalised foods with specific functional properties that meet personal requirements and expectations in relation to flavour, colour, shape, and texture [38]. This could make personalized nutrition more appealing to consumers and to the food industry in the future.

Policy makers and regulatory agencies

Current processes of regulatory agencies are not consistent with personalisation of recommendations and dietary advice. Dietary guidance is currently based on classical endpoint studies using population-based statistics. On the other hand, personal and precision nutrition consider individual requirements based on individual consumer needs and preferences. Data to support the development of recommendations may be generated by new n-of-1-based study designs [39]. The development of new regulatory pathways beyond the reliance on RCTs with classical endpoints may be necessary, possibly including novel approaches assessing individuals’ responses that produce replicated results [13]. Developing machine-learning regulations will be necessary to ensure replicability of data analysis of research and real-world data. An interim step would be to focus on nutritional guidelines for different population groups defined by data consisting of social, lifestyle, and environmental factors.

Another level of complexity for personalisation of recommendations and dietary advice is that guidelines consider whole foods and dietary patterns rather than single nutrients or foods. Although it may seem intuitive that responses to a single nutrient may produce more replicable results, such approaches assume an inflexible metabolic machinery inconsistent with first-principles of biological systems that flexibly respond to changing environments. In addition, one nutrient rarely has a single main mechanism or effect. Omics technologies now permit the elucidation of how combinations of nutrients in foods produce specific metabolic readouts. Nevertheless, developing health claims of the beneficial effects of whole foods and/or diets is challenging and will require new research designs and regulatory guidelines for complex mixtures rather than individual nutrients.

Conclusion

Progress in the field of personalised and precision nutrition aims for a better prediction of individual responses rather than population-based averages. Our current knowledge was based on statistical approaches and study designs that masked inter-individual variability in response to dietary bioactives. Here we make a strong case for more longitudinal and clinical intervention studies that account for inter-individual variability, with the scope of creation of databases that would allow data aggregation, stratification, and fusion to identify how common factors influence ADME and responsiveness to dietary plant bioactives. The knowledge coming from such studies and a collaborative vision to translate results of these efforts to individual and public health will facilitate the establishment of evidence-based, and hence publicly acceptable, health claims that shall support effective marketing strategies to increase consumer understanding and consumption of healthier foods (Fig. 2).

Acknowledgements This article is based upon work from COST Action FA1403 POSITIVe (Interindividual variation in response to consumption of plant food bioactives and determinants involved) supported by COST (European Cooperation in Science and Technology: www.cost.eu). BdR is funded by the Scottish Government Rural and Environment Science and Analytical Services (RESAS) division.

Author contribution All authors contributed to the design and the editing of this review.

Funding COST Action FA1403-European Cooperation in Science and Technology (www.cost.eu).

Compliance with ethical standards

Conflict of interest The authors have declared no conflict of interest.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. Manach C, Milenkovic D, Van de Wiele T, Rodriguez-Mateos A, de Roos B, Garcia-Conesa MT, Landberg R, Gibney ER, Heinonen M, Tomás-Barberán F, Morand C (2017) Addressing the inter-individual variation in response to consumption of plant food bioactives: Towards a better understanding of their role in healthy aging and cardiometabolic risk reduction. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201600557
2. Brett GM, Hollands W, Needs PW, Teucher B, Dainty JR, Bennett RN, Davis BD, Brodbelt JS, Kroon PA (2009) Absorption,
metabolism and excretion of flavanones from single portions of orange fruit and juice and effects of anthropometric variables and contraceptive pill use on flavanone excretion. Br J Nutr 101:664–675

3. González-Sarrías A, García-Villalba R,romo-Vaquero M, Alasalvar C, Örem A, Zafrilla P, Tomás-Barberán FA, Selma MV, Espín JC (2017) Clustering according to urolithin metabotype explains the interindividual variability in the improvement of cardiovascular risk biomarkers in overweight-obese individuals consuming pomegranate: a randomized clinical trial. Mol Nutr Food Res 61(5):1600830

4. Bohn T, Desmarchelier C, Dragstedt LO, Nielsen CS, Stahl W, Rühl R, Keijer J, Borel P (2017) Host-related factors explaining interindividual variability of carotenoid bioavailability and tissue concentrations in humans. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201600685

5. Cassidy A, Minihane AM (2017) The role of metabolism (and the microbiome) in defining the clinical efficacy of dietary flavonoids. Am J Clin Nutr 105:10–22

6. Frankenfeld CL (2017) Cardiometabolic risk and gut microbial phytoestrogen metabolite phenotypes. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201500900

7. Hålldin E, Eriksen AK, Brunius C, da Silva AB, Bronze M, Hanhineva K, Aura AM, Landberg R (2019) Factors explaining interpersonal variation in plasma enterolactone concentrations in humans. Mol Nutr Food Res. https://doi.org/10.1002/mnfr.201811159 (epub ahead of print)

8. Lacroix S, Klicie Badoux J, Scott-Boyer MP, Parolo S, Matone A, Priami C, Morine MJ, Kaput J, Moco S (2018) A computationally driven analysis of the polyphenol-protein interactome. Sci Rep 8:2232

9. Milenkovic D, Morand C, Cassidy A, Konic-Ristic A, Tomás-Barberán F, Ordoñez JM, Kroon P, De Caterina R, Rodríguez-Mateos A (2017) Interindividual variability in biomarkers of cardiometabolic health after consumption of major plant-food bioactive compounds and the determinants involved. Adv Nutr 8:558–570

10. González-Sarrías A, Combet E, Pinto P, Menas J, Dall’Asta M, Garcia-Aloy M, Rodríguez-Mateos A, Gibney ER, Dumont J, Massoro M, Sánchez-Meca J, Morand C, García-Conesa MT (2017) A systematic review and meta-analysis of the effects of flavanol-containing tea, cocoa and apple products on body composition and blood lipids: exploring the factors responsible for variability in their efficacy. Nutrients 9:746

11. García-Conesa MT, Chambers K, Combet E, Pinto P, Garcia-Aloy M, Andrés-Lacueva C, de Pascual-Teresa S, Mená P, Konic Ristic A, Hollands W, Kroon P, Rodríguez-Mateos A, Istars G, Kontogiorgis CA, Rai DK, Gibney ER, Morand C, Espín JC, González-Sarrías A (2018) Meta-analysis of the effects of foods and derived products containing ellagitannins and anthocyanins on cardiometabolic biomarkers: analysis of factors influencing variability of the individual responses. Int J Mol Sci 19:69

12. de Roos B, Brennan L (2017) Personalised interventions—a precision approach for the next generation of dietary intervention studies. Nutrients 9:E847

13. Mathias MG, Colelho-Landell CA, Scott-Boyer MP, Lacroix S, Morine MJ, Salomão RG, Tolfaño RB, Almada MORDV, Cama-neiro JM, Hilleshain E, de Barros TA, Camelio-Junior JS, Campos Giménez E, Redeul K, Goyon A, Bertschy E, Lêvêques A, Obersen JM, Giménez C, Carayol J, Kussmann M, Descobres P, Métairon S, Draper CF, Conus N, Mottaz SC, Corsini G, Myoshi SK, Cialle Rosso M, Cordero CE, Daniel H, Durand S, Ebert B, Ferrario PG, Feskens EJM, Franceschi P, Garcia-Aloy M, Giacomoni F, Gieger C, Hauner H, Daniel H, Djebali S, Brancati LM, Hillekamp F, Ruhnke M, Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Küllerich P, Roager HM, Kristiansen K, Larsen LH, Astrup A (2019) Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post hoc analysis. Int J Obes (Lond) 43:149–157

14. Schaper M, Schicktanz S (2018) Medicine, market and communication: ethical considerations in regard to persuasive communication in direct-to-consumer genetic testing services. BMC Med Ethics 19:56

15. Badalato L, Kalokairinou L, Borry P (2017) Third party interpretation of raw genetic data: an ethical exploration. Eur J Hum Genet 25:1189–1194

16. Regulation (EC) No 1924/2006 of the European Parliament and of the council. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32006R1924&from=en

17. Hick S, Kuljancic N, Wills JM, Pravst I, Kaur A, Raats MM, van Trijp HC, Verbeke W, Grunert KG (2015) The role of health-related claims and health-related symbols in consumer behaviour: Design and conceptual framework of the CLYMBOL project and initial results. Nutr Bull 40:66–72

18. Tomás-Barberán FA, Espín JC (2019) Effect of food structure and processing on (poly)phenols-gut microbiota interactions and effects on human health. Ann Rev Food Sci Technol 10:221–238

19. Hjorth MF, Blædel T, Bendtsen LQ, Lorenzen JK, Holm JB, Küllerich P, Roager HM, Kristiansen K, Larsen LH, Astrup A (2019) Prevotella-to-Bacteroides ratio predicts body weight and fat loss success on 24-week diets varying in macronutrient composition and dietary fiber: results from a post hoc analysis. Int J Obes (Lond) 43:149–157

20. Kovatcheva-Datchary P, Nilsson A, Akrani R, Lee YS, De Vader F, Azora T, Hallen A, Martens E, Björck I, Bäckhed F (2015) Dietary fiber-induced improvement in glucose metabolism is associated with increased abundance of Prevotella. Cell Metab 22:971–982

21. Selma MV, Romo-Vaquero M, García-Villalba R, González-Sarrías A, Tomás-Barberán FA, Espín JC (2016) The human gut microbial ecology associated with overweight and obesity determines ellagic acid metabolism. Food Funct 7:1769–1774

22. Bolca S, Possemiers S, Maeroyt V, Huybrechts I, Heyrick A, Verarcke S, Depeytere H, De Keukeleire D, Bracke M, De Henauw S, Verstraete W, Van de Wiele T (2007) Microbial and dietary factors associated with the 8-prenylnaringenin producer phenotype: a dietary intervention trial with fifty healthy post-menopausal Caucasian women. Br J Nutr 98:950–959

23. Kaput J, van Ommen B, Kremer B, Priami C, Monteiro JP, Morine M, Pepping F, Díaz Z, Fenech M, He Y, Albers R, Drevon CA, Evelo CT, Hancock RE, Jølsmarud C, Lumey LH, Minihane AM, Muller M, Murgia C, Radonicj M, Sobral B, West KP Jr. (2014) Consensus Statement—understanding health and malnutrition through a systems approach: the ENOUGH program for early life. Gen Nutr 9:378

24. Ulaszewksa MM, Weinert CH, Trinigo A, Portmann R, Andres Lacueva C, Badertscher R, Brennan L, Brunius C, Bab A, Capozzi F, Cialié Rosso M, Cordero CE, Daniel H, Durand S, Ebert B, Ferrario PG, Feskens EJM, Franceschi P, Garcia-Aloy M, Giacomoni F, Giebertz P, González-Dominguez R, Hanhineva K, Hemeryck LY, Kopka J, Kulling SE, Llorach R, Manach C, Mattivi F, Microbiome studies. Nutrients 9:E847

25. Riedl A, Gieger C, Hauner H, Daniel H, Linseisen J (2017) Metabotyping and its application in targeted nutrition: an overview. Metab Res 63:e1800384

26. Riedl A, Gieger C, Hauner H, Daniel H, Linseisen J (2017) Metabotyping and its application in targeted nutrition: an overview. Br J Nutr 117:1631–1644

27. Koistinen VM, da Silva AB, Abrânkó L, Low D, Villalba RG, Barberán FT, Landberg R, Savolainen O, Alvarez-Acero I, de Pascual-Teresa S, van Poucke C, Almeida C, Petrásková L, Valenková K, Durand S, Wiczkowski S, Szawara-Nowak D,
on health-related behaviour change: evidence from the Food4Me European randomized controlled trial. Int J Epidemiol 46:578–588
32. Stewart-Knox B, Rankin A, Kuznesof S, Poinhos R, Vaz de Almeida MD, Fischer A, Frewer LJ (2015) Promoting healthy dietary behaviour through personalised nutrition: technology push or technology pull? Proc Nutr Soc 74:171–176
33. Grundy Q, Chiu K, Held F, Continella A, Bero L, Holz R (2019) Data sharing practices of medicines related apps and the mobile ecosystem: traffic, content, and network analysis. BMJ. https://doi.org/10.1136/bmj.i920
34. Berezowska A, Fischer AR, Ronteltap A, van der Lans IA, van Trijp HC (2015) Consumer adoption of personalised nutrition services from the perspective of a risk-benefit trade-off. Genes Nutr 10:42
35. O’Donovan CB, Walsh MC, Gibney MJ, Brennan L, Gibney ER (2017) Knowing your genes: does this impact behaviour change? Proc Nutr Soc 76:182–191
36. Hollands GJ, French DP, Griffin SJ, Prevost AT, Sutton S, King S, Marteau TM (2016) The impact of communicating genetic risks of disease on risk-reducing health behaviour: systematic review with meta-analysis. BMJ 352:i1102
37. de Roos B (2013) Personalised nutrition: ready for practice? Proc Nutr Soc 72:48–52
38. Derossi A, Husain A, Caporizzi R, Severini C (2019) Manufacturing personalized food for people uniqueness. An overview from traditional to emerging technologies. Crit Rev Food Sci Nutr 22:1–19
39. Schork NJ, Goetz LH (2017) Single-subject studies in translational nutrition research. Annu Rev Nutr 37:395–422

Affiliations

Baukje de Roos1, Anna-Marja Aura2, Maria Bronze3, Aedin Cassidy4, María-Teresa García Conesa5, Eileen R. Gibney6, Arno Greyling7, Jim Kaput8, Zohar Kerem9, Nada Knežević10, Paul Kroon11, Rikard Landberg12, Claudine Manach13, Dragan Milenkovic13, Ana Rodríguez-Mateos14, Francisco A. Tomás-Barberán5, Tom van de Wiele15, Christine Morand13

1 The Rowett Institute, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK
2 VTT Technical Research Centre of Finland, PO Box 1000, Tietotie 2, Espoo, Finland
3 Instituto de Biología Experimental e Tecnológica, Apartado 12, Oeiras, Portugal
4 Department of Nutrition and Preventive Medicine, Norwich Medical School, University of East Anglia, Norwich, UK
5 Food and Health Laboratory, Research Group on Quality, Safety, and Bioactivity of Plant Foods, CEBAS-CSIC, Campus de Espinardo, Murcia, Spain
6 UCD Institute of Food and Health, School of Agriculture and Food Science, University College Dublin, Dublin, Ireland
7 Unilever Research and Development Vlaardingen, Vlaardingen, The Netherlands
8 Vydiant, Sacramento, CA 95816, USA
9 R.H. Smith Faculty of Agriculture, Food and Environment, The Hebrew University of Jerusalem, Jerusalem, Israel
10 Podravka d.d, 48000 Koprivnica, Croatia
11 Quadram Institute Bioscience, Norwich Research Park, Norwich, UK
12 Division of Food and Nutrition Science, Department of Biology and Biological Engineering, Chalmers University of Technology, Gothenburg, Sweden
13 INRA, UNH, Unité de Nutrition Humaine, CRNH Auvergne, Université Clermont Auvergne, Clermont-Ferrand, France
14 Department of Nutritional Sciences, Faculty of Life Sciences and Medicine, School of Life Course Sciences, King’s College London, London, UK
15 Faculty of Bioscience Engineering, Center for Microbial Ecology and Technology, Ghent University, Ghent, Belgium